All In MedTech

Device Trial Radar · NCT07786025

DisTal Arterio-Venous Fistula Feasibility

Feasibility Study to Assess the Safety and Efficacy of the DisTal Arterio-Venous Fistula Procedure

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Actual

Start

Dec 2, 2024

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Lead sponsor
Distal Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 25, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate, in a clinical setting, the feasibility of vein enlargement at the site of the arteriovenous fistula created percutaneously, using the DisTal device ("DisTal AVF"). The main question the study aims to answer is what is the rate of successful enlargement of the vein at the site of DisTal AVF within 100 days of the procedure, as confirmed by ultrasound.

Conditions

  • End-Stage Renal Disease Requiring Haemodialysis

Interventions

  • DisTalDevice

    To create a DisTal arteriovenous fistula, the radial vein and radial artery are accessed percutaneously. Venous and arterial guidewires are inserted-with the arterial wire navigating from the vein into the artery-and aligned in position. The DisTal device, featuring a circular blade on a torque shaft, is advanced over both wires. As it advances, DisTal pulls the vessels together while the blade cuts a 7-10 mm opening between the adjoining artery and vein, establishing a non-surgical, endovascular arteriovenous fistula that allows direct blood flow.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percutaneous DisTal AVF vein enlargement success rateTime frame: within 100 days of establishing DisTal AVF

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica Canela

    La Romana, Dominican Republic

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.